Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC
Status:
Not yet recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
This phase 2 study is designed to evaluate the safety and activity of apatinib,a tyrosine
kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2,
in combination with EGFR-TKI in NSCLC with T790M-negative after the failure of EGFR-TKI
therapy.